TITLE: Chief Executive Officer

ORGANIZATION: Global Alliance for TB Drug Development (TB Alliance)

LOCATION: New York, New York

REPORTING RELATIONSHIP: The Chief Executive Officer will report to the Board of Directors.

ORGANIZATION BACKGROUND: The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 with seed funding from the Rockefeller Foundation and the Bill and Melinda Gates Foundation (BMGF) to accelerate the development of new TB drugs. A not-for-profit, Public-Private Product Development Partnership (PD-PPP), the TB Alliance is developing the most comprehensive portfolio of TB drug candidates in the world to produce new TB treatments that are shorter, effective against susceptible and resistant strains of TB, compatible with antiretroviral therapies and that will improve the cure of latent infection.

The innovative PD-PPP business model employs the practices and dynamism of the private sector in pursuit of its social mission. A virtual research and development (R&D) organization, the TB Alliance carries out its activities cost effectively by active and strategic milestone-based portfolio management, concentrating resources to fill the gaps in the R&D pipeline and acquiring or licensing promising anti-TB compounds. Compounds are moved through the development pipeline swiftly by working in collaboration with public and private institutions or with contract research organizations. The TB Alliance provides staged funding and expert scientific and management guidance to advance promising drug combinations and helps catalyze world-wide TB drug development. Currently, the TB Alliance has two drugs in clinical trials, moxifloxacin and PA-824, and a significant pipeline of late stage discovery/pre-clinical drug candidates. It expects to submit a moxifloxacin-containing regimen for regulatory approval before the end of 2010.

In addition to safety and efficacy, issues of affordability, adoption and availability are part of the Alliance’s drug development process, influencing the priority setting, compound selection, and intellectual
property management. All agreements signed incorporate strategic intellectual property rights clauses, and, as appropriate, involve endemic country expertise and service providers. Further, the TB Alliance works closely with international organizations, such as the Stop TB Partnership and the World Health Organization (WHO), having established itself as the “go to” organization for technical expertise on TB drug development.

The TB Alliance is managed by an executive team that operates under the guidance of a Board of Directors, consisting of 13 representatives from public and private sectors. The Stakeholders Association (SHA), a formal body of the TB Alliance, represents 40 institutions committed to supporting the organization and its activities. In addition, the TB Alliance counts with the important contribution of its Scientific Advisory Committee (SAC). The Alliance operates with the support of the Bill & Melinda Gates Foundation, the UK Department for International Development (DFID), the United States Agency for International Development (USAID), the Netherlands Ministry of Foreign Affairs (DGIS), and Irish Aid.

The TB Alliance is poised for a dramatic expansion. Over the next five years the TB Alliance will double in personnel, substantially expand operations in South Africa, China, India, Brazil and other strategic endemic countries, and face the new challenges brought about by its success to date, including manufacturing, intellectual property and galvanizing key stakeholders to adopt new transformational regimens.

**POSITION SUMMARY:** Reporting to and working with the Board of Directors, the Chief Executive Officer is responsible and accountable for the overall programmatic, financial and operational management of the organization. The CEO will help articulate and implement the strategic vision of the TB Alliance as it embarks on an ambitious and critical expansion of operations and activities. The CEO is also responsible for representing the TB Alliance and its mission to the global community, raising awareness about the need for new TB therapies, and soliciting support, financial and otherwise, for anti-TB efforts.
RESPONSIBILITIES: Specific CEO responsibilities include:

Set strategy and objectives
- Develop, communicate and implement goals, priorities and objectives
- Identify opportunities, issues and creative solutions
- Develop and recommend strategies to the Board
- Solicit financial and other support from public, private, and nonprofit organizations

Provide operational leadership and managerial oversight
- Select and develop key executives to foster an environment for productivity and innovation
- Oversee human resource management and maintain a world-class, diverse staff
- Assign priorities, accountabilities, and key performance metrics
- Integrate TB Alliance efforts across functional areas
- Garner resources to properly fund the mission and business of the TB Alliance
- Establish, along with other senior managers, business processes and (re)design the organization to best support these activities

Establish appropriate operational and financial controls
- Ensure that asset management and programs are ethical, transparent and aligned with the organization’s values and goals
- Meet financial requirements, including solvency, fundraising efficiency, and tax-exempt status
- Set financial goals and policies

Create understanding and positive image of the TB Alliance
- Cultivate positive relationships with key constituencies and stakeholders in the TB field throughout the world
- Build relationships with and educate public entities, NGOs, nonprofits, private enterprises, the media, and the public about the issues surrounding tuberculosis drug development and the TB Alliance’s efforts to resolve them
CANDIDATE QUALIFICATIONS: The TB Alliance is seeking a unique individual with outstanding leadership that will direct his or her entrepreneurial spirit for a social goal. Qualified candidates will have an advanced degree in a relevant discipline, with a professional profile that is recognized as a leader and authority among peers. He/she will have substantial experience in drug development and successful drug registration, and demonstrated expertise in managing complex organizations in the biomedical field. Given the nature of the organization, the new CEO must combine strong technical expertise with the skills to successfully navigate global political pressures, fostering solutions and collaboration.

The individual sought will be a strategic thinker able to articulate and attain goals with proven success in raising funds and demonstrated experience developing and managing programs and/or services to achieve worldwide objectives. He/she must promote and encourage innovation and knowledge sharing in an environment conducive to teamwork with the capacity to build alliances and collaborations to achieve joint objectives. To be successful, the candidate will need a proven ability to recruit, motivate and develop talented individuals from diverse backgrounds.

The position requires an individual of high intelligence and unwavering commitment to the TB Alliance’s global social mission. He/she must possess excellent communication skills, written and oral, and have unquestioned personal and professional integrity.

EDUCATION: An advanced degree in a relevant discipline.

COMPENSATION: This is an outstanding career opportunity with a very competitive compensation and benefits program.

CONTACTS:  

Stephen H. Israel
Managing Director
Biotechnology & Pharmaceuticals
Korn/Ferry International
200 Park Avenue
New York, NY 10166
(212) 984-9374 Direct
(212) 986-5684 Fax
Stephen.Israel@kornferry.com

Mary Feely Moriarty
Senior Client Partner
Biotechnology & Pharmaceuticals
Korn/Ferry International
265 Franklin Street
Boston, MA 02110
(617) 790-5755 Direct
(617) 345-0544 Fax
Mary.Moriarty@kornferry.com